Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04372602 · ClinicalTrials.gov registry record · Phase 2
Duvelisib to Combat COVID-19
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT04372602 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 28 participants.
The verdict
NCT04372602, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
The exceedingly high mortality rates of severe and critical COVID-19 warrant the identification and evaluation of novel therapies that could potentially mitigate the advanced disease manifestations. Based on preclinical data from this institution and others, the investigators hypothesize that PI3K inhibition with duvelisib could potentially quell aberrant hyperactivtation of the innate immune system, preferentially polarize macrophages, reduce pulmonary inflammation, and limit viral persistence, thereby improving patient outcomes.
Interventions
- DRUG Placebo
- DRUG Duvelisib
- PROCEDURE Peripheral blood draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2020-10-12 |
| Est. Completion | 2022-03-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04372602
The ClinicalTrials.gov registry entry for NCT04372602 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04372602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04372602 about?
NCT04372602 is a clinical study titled "Duvelisib to Combat COVID-19". The exceedingly high mortality rates of severe and critical COVID-19 warrant the identification and evaluation of novel therapies that could potentially mitigate the advanced disease manifestations. Based on preclinical data from this institution and others, the investigators hypothesize that PI3K i...
What is the current status of trial NCT04372602?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2020-10-12. Estimated completion is 2022-03-02.
What interventions are being tested in trial NCT04372602?
The interventions under investigation include: Placebo (DRUG), Duvelisib (DRUG), Peripheral blood draw (PROCEDURE).
Who is sponsoring clinical trial NCT04372602?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.